The total return over the past 12 months is -11.92% vs. +16.94% for the S&P 500. So far it's up +65.56% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (11.92%) | +15.80% | (15.17%) | (37.18%) | N/A | N/A |
| Total Return CAGR | (11.92%) | +15.79% | (15.17%) | (37.18%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | (773.09%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Eledon Pharmaceuticals, Inc. (ELDN)
| Year | Start price | End price | ELDN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.51 | $2.50 | +65.56% | +14.51% | +51.05% |
| 2025 | $4.12 | $1.51 | (63.35%) | +17.72% | (81.07%) |
| 2024 | $1.80 | $4.12 | +128.89% | +24.89% | +104.00% |
| 2023 | $2.28 | $1.80 | (21.05%) | +26.19% | (47.24%) |
| 2022 | $4.41 | $2.28 | (48.30%) | (18.17%) | (30.13%) |
| 2021 | $15.40 | $4.41 | (71.36%) | +28.74% | (100.10%) |
| 2020 | $10.44 | $15.40 | +47.51% | +18.37% | +29.14% |
| 2019 | $28.80 | $10.44 | (63.75%) | +31.22% | (94.97%) |
| 2018 | $73.08 | $28.80 | (60.59%) | (4.56%) | (56.03%) |
| 2017 | $158.44 | $73.08 | (53.88%) | +21.70% | (75.58%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
